Cantor Fitzgerald Maintains Overweight Rating on Gilead Sciences Following Positive HIV Trial Results
Cantor Fitzgerald reiterated its Overweight rating and $155 price target for Gilead Sciences (GILD) after the company reported positive phase 3 trial results for a weekly HIV treatment. The firm also noted negative findings from another study involving Trodelvy in lung cancer, while RBC Capital reaffirmed its Sector Perform rating.
Topics: Clinical Trials HIV Research Pharmaceuticals Stock Rating